Masimo Corp

Masimo Corp(MASI)の株式分析

$179.950

+0.018 (+0.01%)終値時点

Loading chart…
High
179.990
Open
179.950
VWAP
179.96
Vol
3.16M
Mkt Cap
6.99B
Low
179.950
Amount
568.70M
EV/EBITDA, TTM
21.69

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.

AI analysis of Masimo Corp (MASI)

sell

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

Analyst Ratings (6)

+4.70% upside
Buy
3 Buy
3 Hold
0 Sell
Current: 179.95
安値
162.00
平均
188.40
高値
210.00

Raymond James

2026-03-27

目標株価

$180

Market Perform

Wells Fargo

2026-03-18

目標株価

$180

Equal Weight

Wells Fargo

2025-12-05

目標株価

$190

Overweight

BTIG

2025-12-04

目標株価

$200

Buy

BofA

2025-11-17

目標株価

$162

Neutral

バリュエーション指標

The current forward P/E ratio for Masimo Corp (MASI) is 40.82, compared to its 5-year average forward P/E of 36.31.

Forward P/E

Fair
5Y Average P/E
36.31
Current P/E
40.82
割高
47.34
割安
25.29

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
21.47
Current EV/EBITDA
21.69
割高
28.28
割安
14.65

Forward P/S

Fair
5Y Average P/S
4.63
Current P/S
5.39
割高
6.95
割安
2.30

Alphio AI Price Scenarios for MASI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MASI

$166.97

シナリオ価格

B

Base

Base · 50%MASI

$159.11

シナリオ価格

B

Bear

Bear · 25%MASI

$157.95

シナリオ価格

Whales holding MASI

R

RTW Investments, LP

+ HoldingMASI

+15.57%

3M Return

S

Sofinnova Investments, Inc.

+ HoldingMASI

+15.48%

3M Return

A

Alyeska Investment Group, L.P.

+ HoldingMASI

-0.45%

3M Return

W

Westfield Capital Management Company, L.P.

+ HoldingMASI

-0.72%

3M Return

MASI FAQ — answered by Alphio AI

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

6 analysts cover MASI: 3 rate it Buy, 3 Hold and 0 Sell. The average price target is 188.40.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める